Liver transplant patients who receive checkpoint inhibitors for the treatment of cancer may be at increased risk for injury or loss of the donor organ, new research shows.
In patients who have undergone a liver transplant, a systematic review of the literature suggests there is a risk for graft injury and graft loss in liver transplant recipients who are treated with immune checkpoint inhibitors.
A systematic review of the literature found as many as one-third of transplant patients exposed to